Complex Generics and Hybrid Roles
Generic manufacturing in 2026 has moved beyond simple "copycat" pills. The focus has shifted to Complex Generics—drugs with intricate active ingredients, such as peptides or polymeric compounds, or complex delivery systems like auto-injectors and transdermal patches.
Technical Challenges: These products require sophisticated bioequivalence studies and advanced manufacturing processes.
Industry Transformation: This shift has created new hybrid roles in the workforce, such as AI-clinical analysts and data-driven pharmacovigilance specialists, who use machine learning to ensure that complex generic formulations behave identically to their brand-name counterparts.
7 Views